Alliance Pharma PLC Hardman Research: Kelo-cote international sales

TIDMAPH

Alliance Pharma PLC

17 October 2017

Hardman Research: Kelo-cote building international sales

Kelo-cote building international sales - Alliance Pharma's buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma has transformed the company into an internationally brand-oriented business. Performance of the enlarged group is being driven by two international growth brands, Kelo-cote and MacuShield, which are exceeding expectations, supported by bedrock products. Although the MHRA did not approve Diclectin, discussions continue which may or may not lead to reconsideration. Meanwhile, this will not impact the near-term financial performance.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/17.10.17-kelo-cote-building-international-sales.pdf

 
 To contact us:         Contacts: 
  Hardman & Co           Dr Martin Hall 
  35 New Broad Street    [e-mail] 
  London                 Dr Dorothea Hill 
  EC2M 1NH               [e-mail] 
                         Dr Gregoire Pave 
                         [e-mail] 
                         Telephone: [phone] 
                         Follow us on Twitter @HardmanandCo 
 

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGIBDGBBBBGRR

(END) Dow Jones Newswires

October 17, 2017 04:14 ET (08:14 GMT)